NZ279443A - Solubilizing difficultly soluble pharmaceutical agents using a mixture of polyethylene glycol, polyvinylpyrrolidone and propylene glycol - Google Patents

Description

New Zealand Paient Spedficaiion for Paient Number £79443 New Zealand No. 279443 International No. PCT/US95/01018 TO BE ENTERED AFTER ACCEPTANCE AND PUBLICATION Priority dates: 24.01.1994; Complete Specification Filed: 24.01.1995 Classification:^) A61K47/10,32,22; A61K9/08 Publication date: 27 April 1998 Journal No.: 1427 Title of Invention: Process for solubilizing difficultly soluble pharmaceutical actives Name, address and nationality of applicant(s) as in international application form: THE PROCTER & GAMBLE COMPANY, a US company of One Procter & Gamble Plaza, Cincinnati, Ohio 45202, United States of America NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION 279443 1 PROCESS FOR SOLUBILIZING DIFFICULTLY SOLUBLE PHARMACEUTICAL ACTIVES 5 TECHNICAL FIELD The present invention relates to a process for enhancing the solubility of difficultly 10 soluble pharmaceutical actives in a mixture of polyethylene glycol, polyvinylpyrrolidone, and propylene glycol.

BACKGROUND OF THE INVENTION Liquid, and especially concentrated liquid pharmaceutical compositions offer several advantages over solid compositions. Liquids are easy to swallow and provide an 15 excellent vehicle for the uniform delivery of pharmaceutical actives. Moreover, liquids provide a rapid onset of pharmacologic action, since the composition does not first have to disintegrate and dissolve in the gastrointestinal tract. Likewise, concentrated liquid compositions offer certain distinct advantages. These compositions are ideally suited for incorporation into easy-to-swallow soft, flexible capsules. Encapsulation of this nature 20 permits the accurate and uniform delivery of unit dose amounts of a pharmaceutical active, encompassing even those instances where relatively small amounts of a pharmaceutical active are to be delivered. In addition, soft gelatin capsules are aesthetically appealing (especially when filled with a transparent liquid) and can be manufactured in a wide variety of sizes, shapes, and colors.

These advantages notwithstanding, it is often difficult to prepare such com positions using the desired pharmaceutical active however. Many pharmaceutical actives are poorly soluble and, therefore, require relatively large volumes of solvent for dissolution, resulting in unpractically large doses. Also, encapsulating such large volumes into easy-to-swallow gelatin capsules presents obvious difficulties, suggesting the 30 immediate importance of concentrated liquid compositions. Furthermore, the situation v becomes even more complicated when multiple pharmaceutical actives are involved, and particularly where the difficultly soluble pharmaceutical active is in combination with a water soluble pharmaceutical active(s).

The current approach to this solubility problem is to force solubility into small 35 volumes of solvent by means of a step-wise process incorporating heat. This step-wise process consists of dissolving the difficultly soluble pharmaceutical active in polyethylene *> glycol with heat, followed by the addition of any additional pharmaceutical actives. As a separate admixture, polyvinylpyrrolidone is dissolved in a solution of water and propylene glycol. Finally, the polyvinylpyrrolidone solution is then added to the original batch solution to complete the process. Because the resultant concentrated liquid (or fill) is a 5 supersaturated solution of the difficultly soluble pharmaceutical active, it is even more difficult to increase the resultant composition's concentration of the difficultly soluble active.

The present inventor has discovered that by using a polyvinylpyrrolidone with a specific viscosity average molecular weight of from about 5,000 to about 25,000 provides 10 dissolution of significantly higher levels of the difficultly soluble pharmaceutical active.

It is, therefore, an object of the present invention to describe a process which provides for increased solubility of difficultly soluble pharmaceutical actives. A further object of the present invention is to enhance stability of the resultant composition by reducing the tendency of the difficultly soluble pharmaceutical active to precipitate out of 15 solution. These and other objects of this invention will become apparent in light of the following discussion.

SUMMARY OF THE INVENTION The present invention relates to a process for enhancing the solubility of difficultly soluble pharmaceutical actives by combining and mixing until dissolved from about 1% to 20 about 40% of at least one difficultly soluble pharmaceutical active in a solution comprising: i) from about 20% to about 70% of a polyethylene glycol; ii) from about 4% to about 20% of a polyvinylpyrrolidone having a viscosity average molecular weight from about 5,000 to about 25,000; and iii) from about 1% to about 10% of a propylene glycol.

The process preferably further comprises combining and mixing until dissolved the above solution with a separate admixture of from about 0.5% to about 20% of at least one additional pharmaceutical active in from about 1% to about 50% of an aqueous phase.

All percentages and ratios used herein are by weight and all measurements are at 30 25°C, unless otherwise indicated.

DETAILED DESCRIPTION OF THE INVENTION The term "difficultly soluble pharmaceutical active", as used herein, describes an active having a solubility of less than or equal to 1% by weight in water at 25°C. This term is defined to also include the descriptive terms "sparingly soluble"; "slightly soluble"; 35 "very slightly soluble"; "practically insoluble, or insoluble"; and their equivalents as defined WO 95/19759 PCT/US95/01018 in the USP XXII. p.8 (1990), this reference being incorporated herein by reference in its entirety.

Concentrated Liquid Pharmaceutical Compositions The highly concentrated liquid pharmaceutical compositions of the present invention comprise the following essential, as well as optional, components.

Polyethylene Glycol An essential component of the present compositions is a polyethylene glycol. 10 Polyethylene glycols generally are clear, viscous liquids or white solids which are soluble in water and many organic solvents. These polymers correspond to the general formula: H(OCH2CH2)nOH where n is greater than or equal to 4. Polyethylene glycols are described in G.M. Powell, III in Handbook of Water-Soluble Gums & Resins. R.L. Davidson, Ed. (McGraw-Hill, 15 New York, 1980) pp. 18/1-18/31, this reference being incorporated herein by reference in its entirety. Polyethylene glycols, which are also known as "PEGs" or "polyoxyethylenes", are designated by both their average molecular weight range and their average "n" value as in the above designated formula. For example, polyethylene glycol 400, which is also known by the CTFA designation, PEG-8, has an average molecular weight range from 20 3 80-420 and an average value of n between 8.2 and 9.1. See CTFA Cosmetic Ingredient Dictionary. Third Edition (1982), pp. 201-203; and The Merck Index. Tenth Edition, entry 7441, p. 1092 (1983); these two references being incorporated herein by reference in their entirety.

Polyethylene glycols useful herein are mixtures of those which are liquids at room 25 temperature or have a melting point slightly thereabove. Preferred mirtures include those polyethylene glycols having a molecular weight range of from about 300 to about 1000 and corresponding n values of from about 6 to about 20. More preferred are those of polyethylene glycols having a molecular weight range of from about 400 to about 1000 and corresponding n values of from about 8 to about 20. Most preferred are those of 30 polyethylene glycols having a molecular weight range of from about 600 to about 1000 and corresponding n values of from about 12 to about 20. Liquid and low-melting polyethylene glycols are commercially available from Union Carbide (Danbury, CT) under the Carbowax® trademark. See "Carbowax® Polyethylene Glycols", Union Carbide Technical Bulletin f-4772M-ICD 11/86-20M, this reference being incorporated herein by 35 reference in its entirety WO 95/19759 PCT/US95/01018 4 Polyethylene glycols having an average molecular weight below about 300 are not desirable for use in the instant invention since such polyethylene glycols tend to diffuse into, plasticize, and ultimately disrupt the soft gelatin shells which can be employed to encapsulate the compositions described herein.

The process for preparing the highly concentrated liquid compositions of the present invention comprises adding from about 20% to about 70% polyethylene glycol, more preferably from about 30% to about 60%, and most preferably from about 35% to about 55%.

Polyvinylpyrrolidone An essential component of the present compositions is polyvinylpyrrolidone ("PVP"), which is a polymer of N-vinyl-2-pyrrolidone having the following formula: CH cti Polyvinylpyrrolidones are described in L. Blecher et al. in Handbook of Water-Soluble Gums & Resins. R.L. Davidson, Ed. (McGraw-Hill, New York, 1980) pp. 21/1-21/21, this reference being incorporated herein by reference in its entirety. Polyvi-nylpyrrolidone has different solubility characteristics based on its polymeric structure. Long-chain polyvinylpyrrolidone, which is also known as povidone, has good solubility in 20 water and a number of organic solvents. Cross-linked polyvinylpyrrolidone, which is also known as crospovidone, is insoluble in virtually all common solvents. Both the soluble and insoluble forms of polyvinylpyrrolidone are commercially available from GAF Chemicals Company (Wayne, NJ) under the Plasdone® and Polyplasdone® trademarks, respectively, and from BASF Aktiengesellschaft (Ludwigshafen, Germany) under the 25 Kollidon® trademark. Soluble forms of polyvinylpyrrolidone include Plasdone® K-25, WO 95/19759 PCT/US95/01018 Plasdone® K-26/28, Plasdone® K-29/32. Plasdone® C-15, Plasdone© C-30, Plasdone® C-90, Kollidon® 12 PF, Kollidon® 17 PF, Kollidon® 25, Kollidon® 30. and Kollidon® 90. Insoluble forms of polyvinylpyrrolidone include Polyplasdone XL®, Polyplasdone XL ® 10, Kollidon® CL, and Kollidon® CL-M. See "Tableting With Plasdone®", GAF 5 Technical Bulletin 2302-11 OR I (1986); "Polyplasdone XL®, Polyplasdone XL® 10", GAF Technical Bulletin 2302-099 R2 (1984); and "Kollidon® Grades, Polyvinylpyrrolidone for the Pharmaceutical Industry", BASF Technical Bulletin MEF 129e, Register 2, May 1986 (Bn); these references being incorporated herein by reference in their entirety.

The soluble forms of polyvinylpyrrolidone are preferred for use in the present inven-10 tion. Preferred are soluble polyvinyl- pyrrolidones having an viscosity average molecular weight in the range from about 5000 to about 25,000; more preferred are those having an viscosity average molecular weight in the range from about 5000 to about 15,000, and most preferred are those having an viscosity average molecular weight from about 5,000 to about 10,000. Moreover, mixtures of two or more soluble polyvinylpyrrolidones of 15 different average molecular weight can be employed.

The process for preparing the highly concentrated liquid compositions of the instant invention comprises adding from about 1% to about 28% of a soluble polyvinylpyrrolidone, more preferably from about 1% to about 15%, and most preferably from about 2% to about 10%.

Preferably, the ratio of the total amount of polyethylene glycol to polyvinylpyr rolidone should be at least about 2.5; 1.

Propylene Glycol Propylene glycol, which is represented by the formula; CH3CHOHCH2OH is well known in the an for its solvent and/or humectant properties. A colorless and viscous liquid, propylene glycol is miscible with water, alcohols and many organic solvents. Propylene glycol is described in Hawlev's Condensed Chemical Dictionary, pp. 970-971, (Revised by Richard J. Lewis, Sr.) (12th ed. 1993, herein incorporated by reference. Propylene glycol suitable for use in the present invention is obtainable from any 30 number of suppliers, Dow Chemical being one.

Difficultly Soluble Pharmaceutical Actives The compositions of the instant invention contain at least one difficultly soluble pharmaceutical active as an essential component. In general, these actives have a solubility less than or equal to about 1 percent by weight in water at 25°C. Useful classes of 35 pharmaceutically-active compounds which can be incorporated into the present WO 95/19759 PCT/US95/01018 compositions include analgesics, anti-inflammatory agents, anti-pyretics, calcium channel blockers, beta-blockers, antibacterials, antidepressants, antidiabetics, anti-emetics, antihistamines, cerebral stimulants, sedatives, anti-parasitics, expectorants, diuretics, decongestants, antitussives, muscle relaxants, anti-Parkinsonian agents, bronchodilators, 5 cardiotonics, antibiotics, antivirals, nutritional supplements (such as vitamins, minerals, fatty acids, amino acids, and the like), and mixtures thereof. Difficultly soluble pharmaceutical actives selected from the non-narcotic analgesics/nonsteroidal anti-inflammatory drugs are especially useful in the present invention. Examples of such drugs are disclosed in U.S. Patent No. 4,522,828, to Sunshine et al., issued June 11, 1985; 10 this patent being incorporated herein by reference in its entirety.

Examples of preferred difficultly soluble pharmaceutical actives useful in the present invention include, but are not limited to, acetaminophen, acetylsalicylic acid, ibuprofen, fenbuprofen, fenoprofen, flurbiprofen, indomethacin, ketoprofen, naproxen, their pharmaceutically-acceptable salts, and mixtures thereof Acetaminophen is especially 15 preferred for use in the present invention.

The process for preparing the highly concentrated liquid compositions of the instant invention comprises adding from about 1% to about 40% of a difficultly soluble pharmaceutical active, more preferably from about 15% to about 35%, and most preferably from about 25% to about 35%.

Additional Pharmaceutical Actives The compositions of the instant invention can optionally contain one or more additional pharmaceutical actives having a solubility greater than the difficultly soluble pharmaceutical actives described above. In general, these actives have a solubility greater than about 1 percent by weight in water at 25°C. Such additional pharmaceutical actives 25 may also be selected from among the pharmaceutical categories previously mentioned.

Specific examples of additional pharmaceutical actives useful in the present invention include, but are not limited to, pseudoephedrine and its salts such as pseu-doephedrine hydrochloride; dextromethorphan and its salts such as dextromethorphan hydrobromide; doxylamine and its salts such as doxylamine succinate; phenindamine and 30 its salts such as phenindamine hydrogen tartrate; pheniramine and its salts such as pheniramine maleate; chlorpheniramine and its salts such as chlorpheniramine maleate; ephedrine and its salts such as ephedrine sulfate; triprolidine and its salts such as triprolidine hydrochloride; diphenhydramine and it salts such as diphenhydramine hydrochloride, diphenhydramine citrate, and diphenhydramine 8-chlorotheophyllinate; 35 phenyltoxylamine and its salts; guaifenesin; phenylpropanolamine hydrochloride; and WO 95/19759 PCT/US95/01018 mixtures thereof. Preferred additional pharmaceutical actives are dextromethorphan hydrobromide, doxylamine succinate, pseudoephedrine hydrochloride, chlorpheniramine maleate, guaifenesin, triprolidine hydrochloride, diphenydramine hydrochloride and mixtures thereof.

A further class of optional actives include those useful in promoting or maintaining healthy skin. Examples of such actives are disclosed in U.S. Patent 5.073.371. to Turner et al. issued December 17, 1991, this patent being incorporated herein by reference in its entirety.

The process for preparing the highly concentrated liquid compositions of the instant 10 invention comprises adding one or more of these optionally additional pharmaceutical actives at a concentration of from about 0.5% to about 20%.

Coolants In addition, the present invention may optionally incorporate a cooling agent or a combination of cooling agents. Suitable cooling agents are those described in U.S. Patent 15 4.136.163. January 23, 1979, to Watson et al., U.S. Patent 4.230.668. October 28, 1980, to Rowsell et al. and U.S. Patent 4.032.661. to Rowsell et al., all of which are herein incorporated by reference. A particularly preferred cooling agent is N-ethyl-p-menthane-3-carboxamide (WS-3 supplied by Sterling Organics), taught by the above incorporated U.S. Patent 4.136.163. Another particularly preferred cooling agent is 3-1-20 menthoxypropane 1,2-diol (TK-10 supplied by Takasago Perfumery Co., Ltd., Tokyo, Japan). This material is described in detail in U.S. Patent 4.459.425. July 10, 1984 to Amano et al. and incorporated herein by reference.

Other Optional Components Optional components which can be incorporated into the compositions of the 25 instant invention include coolants, colorings, flavorings, preservatives lubricants, flow-enhancers, filling aids, anti- oxidants, essences, and other aesthetically pleasing components.

Process for Solubilizins Difficultly Soluble Pharmaceutical Actives The highly concentrated liquid pharmaceutical compositions are prepared using 30 art-recognized principles and methodologies in mixing the ingredients together and in choosing the type of mixing equipment to be used. In a preferred manner of execution, the difficultly soluble pharmaceutical active, polyethylene glycol, propylene glycol and polyvinylpyrrolidone, are combined in the presence of heat.and mixed until dissolved to form a homogeneous solution. Upon dissolution of the difficultly soluble pharmaceutical 35 active, additional pharmaceutical actives may then be added to this batch solution or S dissolved separately in an aqueous phase. The process is completed once all additional pharmaceutical actives have been added, whether by direct addition to the original batch solution and/or by indirectly transferring the separately formed admixture to the original batch.

Soft Gelatin Capsules PCT/IJS95/01018 y Preselected amounts of the highly concentrated liquid pharmaceutical compositions of the present invention can also be encapsulated in a soft gelatin shell. Optionally, the soft gelatin shell is essentially transparent so as to enhance the aesthetic qualities of the capsule. The soft gelatin shells comprise the following essential, as well as optional, 5 components.

Gelatin Gelatin is an essential component of the soft gelatin shells of the instant invention. The starting gelatin material used in the manufacture of soft capsules is obtained by the partial hydrolysis of collagenous material, such as the skin, white connective tissues, or 0 bones of animals. Gelatin material can be classified as Type A gelatin, which is obtained from the acid-processing of porcine skins and exhibits an isoelectric point between pH 7 arid pH 9; and Type B gelatin, which is obtained from the alkaline-processing of bone and animal (bovine) skins and exhibits an isoelectric point between pH 4.7 and pH 5.2. Blends of Type A and Type B gelatins can be used to obtain a gelatin with the requisite viscosity 15 and bloom strength characteristics for capsule manufacture. Gelatin suitable for capsule manufacture is commercially available from the Sigma Chemical Company, St. Louis, Mo. For a general description of gelatin and gelatin-based capsules, see Remingtons' Pharmaceutical Sciences. 16th ed., Mack Publishing Company, Easton, Pa. (1980), page 1245 and pages 1576-1582; and U.S. Patent 4,935,243, to Borkan et al., issued June 19, 20 1990; these two references being incorporated herein by reference in their entirety.

The soft gelatin shell of the capsules of the instant invention, as initially prepared, comprises from about 20% to about 60% gelatin, morg preferably from about 25% to about 50% gelatin, and most preferably from about 40% to about 50% gelatin. The gelatin can be of Type A, Type B, or a mixture thereof with bloom numbers ranging from 25 about 60 to about 300.

Plasticizer A plasticizer is another essential component of the soft gelaiin shells of the instant invention. One or more plasticizers is incorporated to produce a soft gelatin shell. The soft gelatin thus obtained has the required flexibility characteristics for use as an 30 encapsulation agent. Useful plasticizers of the present invention include glycerin, sorbitan, sorbitol, or similar low molecular weight polyols, and mixtures thereof.

The shell of the present invention, as initially prepared, comprises from about 10% to about 35% plasticizer, preferably from about 10% to about 25% plasticizer, and most preferably from about 10% to about 20% plasticizer. A preferred plasticizer useful in the 35 present invention is glycerin.

PCT/US95/0101S Id Water The soft gelatin shells of the instant invention also comprise water as an essential component. Without being limited by theory, the water is believed to aid in the rapid dissolution or rupture of the soft gelatin shell upon contact with the gastrointestinal fluids encountered in the body.

The shell of the present invention, as initially prepared, comprises from about 15% to about 50% water, more preferably from about 25% to about 40% water, and most preferably from about 30% to about 40% water.

Other Optional Components Other optional components which can be incorporated into the soft gelatin shells include colorings, flavorings, preservatives, anti-oxidants, essences, and other aesthetically pleasing components.

Soft Gelatin Shell Preparation and Encapsulation The solubilized pharmaceutical compositions of the present invention can be encapsulated within any conventional soft gelatin shell that is capable of substantially containing the composition for a reasonable period of time. The soft gelatin shells of the instant invention can be prepared by combining appropriate amounts of gelatin, water, plasticizer, and any optional components in a suitable vessel and agitating and/ t stirring while heating to about 65°C until a uniform solution is obtained. This soft gelatin shell preparation can then be used for encapsulating the desired quantity of the solubilized fill composition employing standard encapsulation methodology to produce one-piece, hermetically-sealed, soft gelatin capsules. The gelatin capsules are formed into the desired shape and size so that they can be readily swallowed. The soft gelatin capsules of the instant invention are of a suitable size for easy swallowing and typically contain from about 100 mg to about 2000 mg of the solubilized pharmaceutical active composition. Soft gelatin capsules and encapsulation methods are described in P.K.. Wilkinson et al., "Softgels: Manufacturing Considerations", Drugs and the Pharmaceutical Sciences. 41 (Specialized Drue Delivery Systems'). P. Tyle, Ed. (Marcel Dekker, Inc., New York, 1990) pp.409-449; F.S. Horn et al., "Capsules, Soft", Encyclopedia of Pharmaceutical Technology, vol. 2, J. Swarbrick and J.C. Boylan, eds. (Marcel Dekker, Inc., New York, 1990) pp. 269-284; M.S.. Pate! et al., "Advances in Softgel Formulation Technology" Manufacturing Chemist, vol. 60, no. 7, pp. 26-28 (July 1989); M.S. Patel et al., "Softgel Technology", Manufacturing Chemist, vol. 60, no. 8, pp. 47-49 (August 1989); R.F.

W09S"9759 rCT/BS95/01018 II Jimerson, "Softgel (Soft Gelatin Capsule) Update", Drug Development and Industrial Pharmacy CInterphex '86 Corference). vol. 12, no. 8 & 9, pp. 1133-1144 (1986); and W.R. Ebert, "Soft Elastic Gelatin Capsules: A Unique Dosage Form", Pharmaceutical Technology, vol. 1, no. 5, pp. 44-50 (1977); these references are incorporated by reference herein in their entirety. Methods for tempering soft gelatin capsules are described in U.S. Patent 5.200.191 to Steele et al., herein incorporated by reference. The resulting soft gelatin capsule is soluble in water and in gatrointestinal fluids. Upon swallowing the capsule, the gelatin shell rapidly dissolves or ruptures in the gastrointestinal tract thereby introducing the pharmaceutical actives into the physiological system.

EXAMPLES The following examples further describe and demonstrate embodiments within the scope of the present invention. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention, as many variations thereof are possible without departing from the spirit and scope of the invention.

EXAMPLE I Solubilized Pharmaceutical Composition A highly concentrated solution containing acetaminophen in combination with other pharmaceutical actives is prepared from the following ingredients: Ingredients Weieht % Acetaminophen 31.25 Pseudoephedrine HCI 2.88 Dextromethorphan HBr 1.44 Doxylamine Succinate 0.60 Polyethylene Glycol 600 • 24.38 Polyethylene Glycol 1000 22.14 Propylene Glycol 4.33 Polyvinylpyrollidone' 8.17 Water Purified 4.81 1 Available as Kollidon K-17 PF from BASF Chem.Co. (Viscosity average molecular weight10,000) A solution of the polyethylene glycols, propylene glycol, and polyvinylpyrrolidone is prepared by mixing and warming these compositions to 70°C. Acetaminophen is then dissolved into this solution, stirring and heating the solution to 120°C in the presence of WO 95/19759 PCT/US95/01018 nitrogen. Once the acetaminophen is dissolved the solution is removed from the heat. In a separate container, pseudoephedrine HC1, dextromethorphan HBr and doxylamine succinate are dissolved in water at room temperature by stirring. Finally, this separate admixture is combined with the original batch solution and mixed until uniform.

Examples II-III are further examples of concentrated solutions containing acetaminophen in combination with other pharmaceutical actives and are manufactured in a manner substantially similar to Example I EXAMPLE II Solubilized Pharmaceutical Composition Ineredients Weisht % Acetaminophen 31.25 Pseudoephedrine HC1 2.88 Dextromethorphan HBr 1.44 Doxylamine Succinate 0.60 Polyethylene Glycol 600 24.38 Polyethylene Glycol 1000 22.14 Propylene Glycol 4.33 Polyvinylpyrollidonel 8.17 Water Purified 4.81 1 Available as Kollidon K-12 PF from BASF Chem.Co. (Viscosity average molecular weight = 5,000) EXAMPLE III Solubilized Pharmaceutical Composition Inaredients Weiaht % Acetaminophen 31.25 Pseudoephedrine HC1 2.88 Dextromethorphan HBr 1.44 Chlorpheniramine Maleate 0.19 Polyethylene Glycol 600 24.52 Polyethylene Glycol 1000 22.40 Propylene Glycol 4.33 Polyvinylpyrollidone * 8.17 Water Purified 4.82 1 Available as Kollidon K-17 PF from BASF Chem.Co. (Viscosity average molecular 35 weight» 10,000) WO 95/19759 PCT/US95/01018 ir> EXAMPLE IV Solubilized Pharmaceutical Composition A highly concentrated solution containing acetaminophen and guaifenesin in combination with other pharmaceutical actives is prepared from the following ingredients: Ingredients Weight % Acetaminophen 31.25 Pseudoephedrine HC1 2.88 Dextromethorphan HBr 0.96 Guaifenesin 9.62 Polyethylene Glycol 600 21.12 Polyethylene Glycol 1000 19.26 Propylene Glycol 2.88 Polyvinylpyrollidone 1 8.17 Water Purified 3.86 1 Available as Kollidon K-17 PF from BASF Chem.Co. (Viscosity average molecular weight = 10,000) A solution of polyethylene glycols, propylene glycol, and polyvinylpyrrolidone is prepared by mixing and warming to 70°C. Acetaminophen is then dissolved into this solution, stirring and heating the solution to 120°C in the presence of nitrogen. Once the 20 acetaminophen is dissolved and the solution removed from heat, the guaifenesin is next added and dissolved. In a separate container, pseudoephedrine HC1, dextromethorphan HBr and doxylamine succinate are dissolved in water at room temperature by stirring. Finally, this separate admixture is combined with the original batch solution and mixed until uniform.

EXAMPLE V Solubilized Pharmaceutical Composition Example V is a further example of a concentrated solution containing acetaminophen and guaifenesin in combination with other pharmaceutical actives and is manufactured in a manner substantially similar to Example IV.

Ingredients Weight % Acetaminophen 31.25 Pseudoephedrine HC1 2.88 Dextromethorphan HBr 0.96 Guaifenesin 9.62 Polyethylene Glycol 600 21.12 14 Polyethylene Glycol 1000 19.26 Propylene Glycol 2.88 Polyvinylpyrollidone' 8.17 Water Purified 3.86 1 Available as Kollidon K-12 PF from BASF. Chem.Co. (Viscosity average molecular weight = 5,000) EXAMPLE VI Solubilized Pharmaceutical Composition A highly concentrated solution containing acetaminophen is prepared from the following ingredients Ingredients Weight % Acetaminophen 31.25 Polyethylene Glycol 600 26.96 Polyethylene Glycol 1000 24.48 Propylene Glycol 4.33 Polyvinylpyrrolidone 1 8.17 Water Purified 4.81 ~ 1 Available as Kollidon K-30 from BASF Chem.Co. (Viscosity average molecular weight * 38,000) A solution of the polyethylene glycols, propylene glycol, and polyvinylpyrrolidone is prepared by mixing and warming these components to 70°C. Acetaminophen is then dissolved into this solution, stirring and heating the solution to 120°C in the presence of nitrogen gas. Once the acetaminophen is dissolved, the solution is removed from the heat. Finally, a measured quantity of the aqueous phase is combined with the original batch solution and mixed until uniform.

EXAMPLE VII Solubilized Pharmaceutical Composition A highly concentrated solution containing acetaminophen and pseudoephedrine HC1 is prepared from the following ingredients Ingredients Weight % Acetaminophen 31.25 Pseudoephedrine HCI 2.88 Polyethylene Glycol 600 25.45 Polyethylene Glycol 1000 23.11 Propylene Glycol 4.33 WO 95/19759 PCT/US95/01018 Polyvinylpyrrolidone 1 S.I7 Water Purified 4.81 1 Available as Kollidon K-30 from BASF Chem.Co. (Viscosity average molecular weight « 38,000) A solution of the polyethylene glycols, propylene glycol, and polyvinylpyrrolidone is prepared by mixing and warming these components to 70°C. Acetaminophen is then dissolved into this solution, stirring and heating the solution to 120°C in the presence of nitrogen gas. Once the acetaminophen is dissolved, the solution is removed from the heat. In a separate container, pseudoephedrine HC1 is dissolved in water at room temperature 10 by stirring. Finally, this separate admixture is combined with the original batch solution and mixed until uniform.

EXAMPLE VIII Softgel Capsule Containing a Solubilized Pharmaceutical Composition A soft gelatin capsule is first prepared form the following ingredients: Ingredients Weight % Gelatin 47.00 Glycerin 1 5.00 Water Purified qs 100 The above ingredients are combined in a suitable vessel and heated with mixing at 20 about 65°C to form a uniform solution. Using standard encapsulation methodology, the resulting solution is used to prepare soft gelatin capsules containing approximately 1040 mg. of the compositions of Examples I-VII. The resulting soft gelatin capsules are suitable for oral administration. 279443

Claims (18)

WHAT WE CLAIM IS:

1. A process to enhance solubility of difficulty soluble pharmaceutical actives by combining and mixing until dissolved from 1% to 40% of at least one difficultly soluble pharmaceutical active in a solution comprising: i) from 20% to 70% of a polyethylene glycol; ii) from 4% to 20% of a polyvinylpyrrolidine having a viscosity average molecular weight from 5,000 to 25,000; and iii) from 1% to 10% of a propylene glycol.

2. A process according to claim 1 comprising dissolving from 20% to 40% of said at least one difficulty soluble pharmaceutical active.

3. A process according to claim 1 comprising dissolving from 25% to 35% of said at least one difficulty soluble pharmaceutical active.

4. A process according to any one of the preceding claims wherein the solution comprises from 40% to 60% of a polyethylene glycol.

5. A process according to any one of the preceding claims wherein the polyvinylpyrrolidine has a viscosity average molecular weight from 5,000 to 15,000. '""■S4S f' v E D p0rfy Off,co " 3 to!33i, 279443

6. A process according to any one of claims 1-4 wherein the polyvinylpyrrolidine has a viscosity average molecular weight from 5,000 to 10,000.

7. A process according to any one of the preceding claims further comprising the step of combining and mixing until dissolved the composition of Claim 1 with from 1% to 50% of an aqueous phase.

8. A process according to claim 7 wherein the aqueous phase is water.

9. A process according to any one of the preceding claims wherein the ratio of polyethylene glycol to said difficulty soluble pharmaceutical active and said polyvinylpyrrolidine is from 1:0.3 to 1:0.9 and from 1:0.09 to 1:0.3 respectively.

10. A process according to any one of the preceding claims wherein said difficulty soluble pharmaceutical active is selected from the group consisting of acetaminophen, acetylsalicylic acid, ibuprofen, fenbuprofen, fenoprofen, flubiprofen, indomethacin, naproxen, and mixtures thereof.

11. A process according to claim 10 wherein said difficulty soluble pharmaceutical active is acetaminophen. htoll, &JC octL>*i lLv F- o;°Pa^ Ol!ho n 9 hi\u jijyy;18;279443;

12. A process according to any one of the preceding claims wherein said polyethylene glycol is selected from a group consisting of PEG-6, PEG-8, PEG-9, PEG-10, PEG-12, PEG-14, PEG-16, PEG-18, PEG 20, and mixtures thereof.;

13. A process according to any one of the preceding claims wherein said polyethylene glycol is a mixture of PEG-12 and PEG-20.;

14. A process according to claim 13 wherein the PEG-12 and PEG-20 are present in a ratio of 1:1.;

15. A process according to any one of claims 7, 8 and 9-14 (when dependent on claim 7) wherein one or more additional pharmaceutical actives are added to said aqueous phase and wherein said active is selected from the group of pharmaceutical actives consisting of dextromethorphan HBr, doxylamine succinate, pseudoephedrine HC5, chlorpheniramine maleate, guaifenesin, triprolidine HCJ, diphenhydramine HC5, and mixtures thereof.;

16. A process according to claim 1 and substantially as herein described with reference to any embodiment disclosed.;

17. A pharmaceutical active, the solubility of which has been enhanced by the process of any one of the preceding claims.;" 3 !;m no;19;279443;

18. A composition comprising a difficulty soluble pharmaceutical active dissolved in a solution when prepared by the process of any one of claims 1-16.;Q|\LIBRARY\KCT\CXA1MS\362335-C.KCT;END OF CLAIMS;.. Received;Intellectual Property OUiua n 9 Man 1.^8*